Walleye Capital’s Dianthus Therapeutics DNTH Stock Holding History
Bought
Maintained
Sold
Other funds holding DNTH
Walleye Capital's DNTH Position: Q3 2026 in Review
Walleye Capital increased its Dianthus Therapeutics (DNTH) stake by 90% in Q3 2026, buying an estimated $1.68M and bringing the position to 34,058 shares worth $3M. The position accounts for ﹤0.01% of the portfolio, ranked #2427.
Walleye Capital first reported a position in DNTH in Q4 2021 and has held it in 12 quarters since. The position peaked at $12.9M in Q1 2026. 274 funds tracked by Wall St. Rank hold DNTH as of Q3 2026.
- Walleye Capital held 34,058 shares of Dianthus Therapeutics worth $3M as of Q3 2026.
- Walleye Capital bought 16,177 Dianthus Therapeutics shares in Q3 2026, an estimated $1.68M.
- Dianthus Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #2427 holding.
- Walleye Capital first reported a position in Dianthus Therapeutics in Q4 2021 and has held it in 12 quarters since.
- Walleye Capital's Dianthus Therapeutics position peaked at $12.9M in Q1 2026.
- 274 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2026.
Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.